Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14206437 | 0.81 | MEN1 (0.43) | CYP19A1AAK1CYP3A4TSHRALDH1A1 | |
| SCHEMBL8185669 | 0.80 | GPR35 (0.51) | CYP3A4TSHRALDH1A1TDP1CYP1A2 | |
| SCHEMBL29465814 | 0.80 | TDP1 (0.53) | CYP3A4TSHRALDH1A1TDP1HTT | |
| SCHEMBL14568010 | 0.80 | TSHR (0.38) | CYP3A4TSHRALDH1A1TDP1HTT | |
| SCHEMBL2490861 | 0.80 | TDP1 (0.53) | CYP3A4TSHRALDH1A1TDP1HTT | |
| SCHEMBL1855973 | 0.78 | ALDH1A1 (0.52) | CYP19A1ALDH1A1MAPTMEN1POLB | |
| SCHEMBL16958454 | 0.78 | CYP19A1 (0.41) | CYP19A1AAK1CYP3A4TSHRALDH1A1 | |
| SCHEMBL11838138 | 0.78 | ALDH1A1 (0.51) | CYP3A4TSHRALDH1A1TDP1HTT | |
| SCHEMBL541077 | 0.78 | PARP1 (0.46) | CYP3A4TSHRALDH1A1TDP1HTT | |
| SCHEMBL11482811 | 0.77 | CYP1A2 (0.42) | CYP3A4ALDH1A1CYP2D6TDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1924572-B1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORP (US) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009154645-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009154645-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| EP-1937671-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | SMITHKLINE BEECHAM CORPORATION | 2009-01-01 | — | — | US | disclosed |
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | SMITHKLINE BEECHAM CORPORATION | 2009-01-01 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| EP-1937671-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SmithKline Beecham Corporation (US) | 2008-07-02 | — | — | EP | disclosed |
| EP-1924572-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SmithKline Beecham Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| WO-2007030361-A2 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030366-A1 | REGIOSELECTIVE PROCESS FOR PREPARING BENZIMIDAZOLE THIOPHENES | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005398-A1 | Methods For The Treatment of Central Nervous System Tumors | TUBB3, TUBB6, TUBB | CYP19A1 3002/4885AAK1 4443/4885CYP3A4 1921/4885 |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | ABCB1, ABCG2, CYP3A5 | CYP19A1 1824/4885AAK1 3858/4885CYP3A4 5/4885 |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | CYP19A1 1755/4885AAK1 3463/4885CYP3A4 4/4885 |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | CYP19A1 183/4885AAK1 3400/4885CYP3A4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.